Literature DB >> 26473063

A double-edged sword: CRISPR-Cas9 is emerging as a revolutionary technique for genome editing.

Chun-Xiao Li1, Hai-Li Qian1.   

Abstract

In May 2015, Professor Xiao Yang authored a review on the development of CRISPR-Cas9 techniques in the journal of Military Medical Research. This review provided a valuable overview of this major scientific advance. It has been four years since the first publication of the CRISPR-Cas9 breakthrough (Science. 2012; 337: 816-21). The use of this technique has expanded into various scientific areas and is being developed into a systematic technical platform that may contribute to many bioengineering fields involving DNA sequence editing.

Entities:  

Keywords:  CRISPR-Cas9; Ethical controversy; Genomic engineering

Year:  2015        PMID: 26473063      PMCID: PMC4607175          DOI: 10.1186/s40779-015-0054-1

Source DB:  PubMed          Journal:  Mil Med Res        ISSN: 2054-9369


Correspondence/findings

Dear editor, In May 2015, Professor Xiao Yang authored a review on the development of CRISPR-Cas9 technique in the journal of Military Medical Research [1]. This review provided a valuable overview of this major scientific advance. It has been four years since the first publication of the CRISPR-Cas9 breakthrough [2]. The use of this technique has expanded into various scientific areas and is being developed into a systematic technical platform that may contribute to many bioengineering fields involving DNA sequence editing. The advantages of the CRISPR(Clustered Regularly Interspaced Short Palindromic Repeats)-Cas9 technology include its economy, high efficiency, precise targeting and flexible technical extension compared with traditional DNA sequence modifying measures such as transcription activator-like effector nuclease (TALEN,transcription activator-like (TAL) effector nucleases) [3]. The published literature has shown the utility of CRISPR-Cas9 in both DNA sequence knock-in and knock-out contexts. The alterations can range from single nucleotide editing to the modification of multiple genome-wide genomic sites [4, 5]. It is easy to delete genes in cells or to create genetically modified karyotypes [6]. The CRISPR-Cas-9 strategy is a convenient method of screening functional genes in life processes and disease development. The technology may also be used as a potential “surgical knife” to correct genomic mutations or create new creatures by changing the inherited phenotypes. In addition to the genomic engineering applications that professor Xiao Yang mentioned, the protospacer adjacent motif (PAM) sequence-limited specificity of the CRISPR-Cas9 system has been used to circumvent engineering Cas9 derivatives. This property provides flexibility to CRISPR-Cas9 targeting strategies [7]. Poulami et al. also found another aspect of CRISPR-mediated immunity. The authors found the Type III CRISPR-Cas immune system was able to cleave DNA and RNA during infection [8]. The technique of CRISPR-Cas9 is still in development. If nonhomologous end joining activity is inhibited in vivo, then the efficiency of precise genome editing with CRISPR-Cas9 can be substantially increased [9]. The CRISPR-Cas9 technology does have limitations associated with targeting ability. Several off-target mutations have been detected by genome-sequencing due to its high specificity. This prohibits its potential use in correcting disease-associated mutations [10]. The rapidly expanding application of the CRISPR-Cas9 technique also creates an ethical controversy because it may be used to manipulate human germ cells. Manipulating human germ cells using CRISPR-Cas9 does not present technical obstacles. However, its potential off-target effects must be considered when a genetically modified individual is created with this tool. Each additional step forward will further improve the technology. Therefore, this technique should be used cautiously before modifying human inheritance. A recent publication in the journal Protein & Cell by Junjiu Huang’s group in China revealed the first attempt to modify human tripronuclear zygotes [11]. This report caused a fierce debate regarding whether this research is breaking the ethical ban on modifying the human germ cell genome [12, 13]. Simultaneously, a project led by George Church at Harvard University tried to correct genomic BRCA1(BREAST CANCER 1) mutations to decrease the risk of breast cancer in the next generation. This study was suspended indefinitely. In addition to the ethical concerns, there are technical concerns to address. The current CRISPR-Cas9 technique is not sufficiently mature to adjust human inheritance. The first issue is that CRISPR-Cas9 induces off-target changes to the genome. The second possible issue is that not all of the functions of the candidate gene are fully understood. Therefore, we cannot appreciate the consequences of genome editing in offspring. While we are joyfully celebrating the progress brought to science by the development of CRISPR-Cas9, we must use caution in applying this technology.
  13 in total

1.  Embryo editing sparks epic debate.

Authors:  David Cyranoski; Sara Reardon
Journal:  Nature       Date:  2015-04-30       Impact factor: 49.962

2.  Don't edit the human germ line.

Authors:  Edward Lanphier; Fyodor Urnov; Sarah Ehlen Haecker; Michael Werner; Joanna Smolenski
Journal:  Nature       Date:  2015-03-26       Impact factor: 49.962

Review 3.  Genome editing. The new frontier of genome engineering with CRISPR-Cas9.

Authors:  Jennifer A Doudna; Emmanuelle Charpentier
Journal:  Science       Date:  2014-11-28       Impact factor: 47.728

4.  Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells.

Authors:  Daesik Kim; Sangsu Bae; Jeongbin Park; Eunji Kim; Seokjoong Kim; Hye Ryeong Yu; Jinha Hwang; Jong-Il Kim; Jin-Soo Kim
Journal:  Nat Methods       Date:  2015-02-09       Impact factor: 28.547

5.  Genome-scale CRISPR-Cas9 knockout screening in human cells.

Authors:  Ophir Shalem; Neville E Sanjana; Ella Hartenian; Xi Shi; David A Scott; Tarjei Mikkelson; Dirk Heckl; Benjamin L Ebert; David E Root; John G Doench; Feng Zhang
Journal:  Science       Date:  2013-12-12       Impact factor: 47.728

6.  Co-transcriptional DNA and RNA Cleavage during Type III CRISPR-Cas Immunity.

Authors:  Poulami Samai; Nora Pyenson; Wenyan Jiang; Gregory W Goldberg; Asma Hatoum-Aslan; Luciano A Marraffini
Journal:  Cell       Date:  2015-05-07       Impact factor: 41.582

7.  Applications of CRISPR-Cas9 mediated genome engineering.

Authors:  Xiao Yang
Journal:  Mil Med Res       Date:  2015-05-09

8.  Engineered CRISPR-Cas9 nucleases with altered PAM specificities.

Authors:  Benjamin P Kleinstiver; Michelle S Prew; Shengdar Q Tsai; Ved V Topkar; Nhu T Nguyen; Zongli Zheng; Andrew P W Gonzales; Zhuyun Li; Randall T Peterson; Jing-Ruey Joanna Yeh; Martin J Aryee; J Keith Joung
Journal:  Nature       Date:  2015-06-22       Impact factor: 49.962

9.  CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes.

Authors:  Puping Liang; Yanwen Xu; Xiya Zhang; Chenhui Ding; Rui Huang; Zhen Zhang; Jie Lv; Xiaowei Xie; Yuxi Chen; Yujing Li; Ying Sun; Yaofu Bai; Zhou Songyang; Wenbin Ma; Canquan Zhou; Junjiu Huang
Journal:  Protein Cell       Date:  2015-04-18       Impact factor: 14.870

10.  Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining.

Authors:  Takeshi Maruyama; Stephanie K Dougan; Matthias C Truttmann; Angelina M Bilate; Jessica R Ingram; Hidde L Ploegh
Journal:  Nat Biotechnol       Date:  2015-03-23       Impact factor: 54.908

View more
  4 in total

Review 1.  The Therapeutic Potential of CRISPR/Cas9 Systems in Oncogene-Addicted Cancer Types: Virally Driven Cancers as a Model System.

Authors:  Luqman Jubair; Nigel A J McMillan
Journal:  Mol Ther Nucleic Acids       Date:  2017-06-12       Impact factor: 8.886

2.  CRISPR/Cas9 from bench to bedside: what clinicians need to know before application?

Authors:  Zi-Qing Li; Chao-Hong Li
Journal:  Mil Med Res       Date:  2020-12-08

Review 3.  An Insight into Modern Targeted Genome-Editing Technologies with a Special Focus on CRISPR/Cas9 and its Applications.

Authors:  Fatima Akram; Sania Sahreen; Farheen Aamir; Ikram Ul Haq; Kausar Malik; Memoona Imtiaz; Waqas Naseem; Narmeen Nasir; Hafiza Mariam Waheed
Journal:  Mol Biotechnol       Date:  2022-04-26       Impact factor: 2.860

4.  Mapping the coevolution, leadership and financing of research on viral vectors, RNAi, CRISPR/Cas9 and other genomic editing technologies.

Authors:  David Fajardo-Ortiz; Annie Shattuck; Stefan Hornbostel
Journal:  PLoS One       Date:  2020-04-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.